The use of immune checkpoint inhibitors (ICIs) offers new possibilities in modern treatment of many types of cancers. Few data regarding safety and efficacy of ICIs are available, and are mainly from retrospective studies and case reports rather than from clinical trials, in the context of preexisting autoimmune disease, mainly due to the risk of severe toxicity. We present an unexpected life-threatening reactivation of systemic lupus erythematosus after one dose of chemo-immunotherapy with pembrolizumab for oligometastatic non-small-cell lung cancer. We analyze data coming from the published literature in this setting and discuss the risk–benefit balance of immunotherapy in patients with preexisting severe autoimmune disease.
BoutrosCTarhiniARoutierE, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol2016; 13: 473–486.
2.
MichotJMBigenwaldCChampiatS, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer2016; 54: 139–148.
3.
HodiFSO’DaySJMcDermottDF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med2010; 363: 711–723.
4.
LarkinJChiarion-SileniVGonzalezR, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med2015; 373: 23–34.
5.
KhanSAPruittSLXuanL, et al. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol2016; 2: 1507–1508.
6.
LeeYHWooJHChoiSJ, et al. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus2009; 18: 9–15.
7.
Ramos-Casals, BrahmerJRCallahanMK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim2020; 6: 38.
Abdel-WahabNShahMLopez-OlivoMA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med2018; 168: 121–130.
10.
TisonAQuéréGMiseryL, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol2019; 71: 2100–2111.
11.
LeonardiGCGainorJFAltanM, et al. Safety of programmed death–1 pathway inhibitors among patients with non–small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol2018; 36: 1905–1912.
12.
DanlosF-XVoisinALDyevreV, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer2018; 91: 21–29.
13.
JohnsonDBSullivanRJOttPA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol2016; 2: 234–240.
14.
MenziesAMJohnsonDBRamanujamS, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol2017; 28: 368–376.
15.
KaurADobersteinTAmberkerRR, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience. Medicine2019; 98: e17348–e17348.
TagliamentoMGrossiFPaolinoS, et al. Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy2019; 11: 873–879.
18.
CortelliniAButiSSantiniD, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist2019; 24: e327–e337.
19.
SatoKAkamatsuHMurakamiE, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer2018; 115: 71–74.
20.
HarataniKHayashiHChibaY, et al. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol2018; 4: 374–378.
21.
RicciutiBGenovaCDe GiglioA, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol2019; 145: 479–485.
22.
WangDYSalemJ-ECohenJV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol2018; 4: 1721–1728.
